.Pharmacolibrary.Drugs.ATC.N.N07XX21 .Pharmacolibrary.Drugs.ATC.N.N07XX21| name: | Eplontersen | |
| ATC code: | N07XX21 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 45 | mg |
| volume of distribution: | 13 | L |
| clearance: | 0.24 | L/h |
| other parameters in model implementation | ||
Eplontersen is an antisense oligonucleotide inhibitor of transthyretin (TTR) synthesis, aiming to reduce serum TTR protein levels. It is developed for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in adults. In 2023, Eplontersen (brand name Wainua) was granted FDA approval for this indication.
Pharmacokinetic parameters estimated for subcutaneous administration in adult patients; no peer-reviewed publication with detailed PK model found as of June 2024.